ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Oncology · Lancet · 2026-05-16

In 870 patients aged 18-65 with mantle cell lymphoma, adding ASCT to ibrutinib-containing treatment did not improve 4-year failure-free survival (82% vs 81%; HR 0.86) after a median 54.9 months, but raised grade 3-5 haematological toxicity (54% vs 28%).

RCTn = 870
Dreyling et al. Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network
Haematology · Br J Haematol · 2026-03-30

Secondary analysis of the phase 3 FLAIR trial in untreated CLL: quality-of-life trajectories were similar with ibrutinib-rituximab vs FCR; FCR scores were worse at end of treatment but recovered, and differences did not exceed minimally important thresholds.

Secondary analysis
Allsup et al. Patient-reported health-related quality of life in previously untreated chronic lymphocytic leukaemia: Results from the randomised phase 3 FLAIR trial comparing ibrutinib-rituximab versus fludarabine-cyclophosphamide-rituximab

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.